BEIGENE,LTD. (NASDAQ:BGNE) Files An 8-K Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial
Condition.

On May10, 2017, BeiGene,Ltd. announced its financial results for
the three months ended March31, 2017. A copy of the press release
is furnished as Exhibit99.1 to this Current Report on Form8-K.

The information in this Current Report on Form8-K and Exhibit99.1
attached hereto is intended to be furnished and shall not be
deemed filed for purposes of Section18 of the Securities Exchange
Act of 1934, as amended (the Exchange Act), or otherwise subject
to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act
of 1933, as amended, or the Exchange Act, except as expressly set
forth by specific reference in such filing.

Item9.01 Financial Statements and
Exhibits.

(d) Exhibits.

About BEIGENE, LTD. (NASDAQ:BGNE)

BeiGene, Ltd. is a clinical-stage biopharmaceutical company. The Company is focused in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The Company had used its cancer biology platform to develop four clinical-stage drug candidates, such as BGB-3111, BGB-A317, BGB-290 and BGB-283, as of December 31, 2016. BGB-3111, BGB-290 and BGB-283 are its molecularly targeted agents and is its immuno-oncology agent. BGB-3111 is a potent and highly selective small molecule inhibitor of Bruton’s tyrosine kinase (BTK). BGB-283 is a molecule inhibitor of both the monomer and dimer forms of the RAF kinase. BGB-290 is a molecularly targeted, orally available, potent and highly selective inhibitor of the poly ADP ribose polymerase (PARP) family members. BGB-A317 is an investigational humanized monoclonal antibody against the immune checkpoint receptor, PD-1.

BEIGENE, LTD. (NASDAQ:BGNE) Recent Trading Information

BEIGENE, LTD. (NASDAQ:BGNE) closed its last trading session up +0.51 at 37.95 with 164,154 shares trading hands.